• Buxbaum J. D., Thinakaran G., Koliatsos V., Ocallahan J., Slunt H. H., Price D. L. and Sisodia S. S. (1998) Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J. Neurosci. 18, 96299637.
  • Cai H. B., Wang Y. S., McCarthy D., Wen H. J., Borchelt D. R., Price D. L. and Wong P. C. (2001) BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4, 233234.
  • Callahan M. J., Lipinski W. J., Bian F., Durham R. A., Pack A. and Walker L. C. (2001) Augmented senile plaque load in aged female β-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158, 11731177.
  • Chishti M. A., Yang D. S., Janus C., Phinney A. L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P. E., Carlson G. A., George-Hyslop P. and Westaway D. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 276, 2156221570.
  • Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N. and Ihara Y. (1994) Visualization of Aβ42(43) and Aβ40 in senile plaques with end- specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 13, 4553.
  • Janus C., Chishti M. A. and Westaway D. (2000) Transgenic mouse models of Alzheimer's disease. Biochim. Biophys. Acta 1502, 6375.
  • Kalback W., Watson M. D., Kokjohn T. A., Kuo Y. M., Weiss N., Luehrs D. C., Lopez J., Brune D., Sisodia S. S., Staufenbiel M., Emmerling M. and Roher A. E. (2002) APP transgenic mice Tg2576 accumulate Aβ peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry 41, 922928.
  • Kawarabayashi T., Younkin L. H., Saido T. C., Shoji M., Ashe K. H. and Younkin S. G. (2001) Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21, 372381.
  • Kuo Y. M., Kokjohn T. A., Beach T. G., Sue L. I., Brune D., Lopez J. C., Kalback W. M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M. and Roher A. E. (2001) Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J. Biol. Chem. 276, 1299112998.
  • Lee J. Y., Cole T. B., Palmiter R. D., Suh S. W. and Koh J. Y. (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl Acad. Sci. USA 99, 77057710.
  • McGowan E., Sanders S., Iwatsubo T., Takeuchi A., Saido T., Zehr C., Yu X., Uljon S., Wang R., Mann D., Dickson D. and Duff K. (1999) Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol. Dis. 6, 231244.
  • Mercken M., Brepoels E., De Jong M., Laenen W., Raeymaekers P. and Geerts H. (2000) Specific ELISA systems for the detection of endogenous human and rodent Aβ40 and Aβ42. Neurobiol. Aging 21, S41.
  • Moechars D., Dewachter I., Lorent K., Reverse D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Van Den H. C., Checler F., Godaux E., Cordell B. and Van Leuven F. (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 64836492.
  • Naslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A. D., Tjernberg L. O., Silberring J., Gandy S. E., Winblad B., Gard P. G., Nordstedt C. and Terenius L. (1994) Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer's disease and normal aging. Proc. Natl Acad. Sci. USA 91, 83788382.
  • Saido T. C., Yamao-Harigaya W., Iwatsubo T. and Kawashima S. (1996) Amino- and carboxyl-terminal heterogeneity of [β]-amyloid peptides deposited in human brain. Neurosi. Lett. 215, 173176.
  • Selkoe D. J. (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23A31.
  • Van Dorpe J., Smeijers L., Dewachter I., Nuyens D., Spittaels K., Van Den H. C., Mercken M., Moechars D., Laenen I., Kuiperi C., Bruynseels K., Tesseur I., Loos R., Vanderstichele H., Checler F., Sciot R. and Van Leuven F. (2000) Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am. J. Pathol. 157, 12831298.
  • Vandermeeren M., Geraerts M., Pype S., Dillen L., Van Hove C. and Mercken M. (2001) The functional γ-secretase inhibitor prevents production of amyloid β1–34 in human and murine cell lines. Neurosci. Lett. 315, 145148.
  • Wang J., Dickson D. W., Trojanowski J. Q. and Lee V. M. Y. (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp. Neurol. 158, 328337.
  • Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietrzik C. U., Findlay K. A., Smith T. W., Murphy M. P., Butler T., Kang D. E., Marquez-Sterling N., Golde T. E. and Koo E. H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclo-oxygenase activity. Nature 414, 212216.
  • Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., Schmidt B., Klafki H. W., Maler M., Dyrks T., Bienert M., Beyermann M., Ruther E. and Kornhuber J. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481496.